205 related articles for article (PubMed ID: 27565568)
21. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
22. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
[TBL] [Abstract][Full Text] [Related]
23. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.
Mannheimer B; Wagner H; Östenson CG; Diczfalusy U
PLoS One; 2015; 10(4):e0121984. PubMed ID: 25835492
[TBL] [Abstract][Full Text] [Related]
24. Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.
Björkhem-Bergman L; Nylén H; Eriksson M; Parini P; Diczfalusy U
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):499-502. PubMed ID: 26617265
[TBL] [Abstract][Full Text] [Related]
25. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
26. Serum 4β-hydroxycholesterol increases during fluconazole treatment.
Lütjohann D; Stellaard F; Kerksiek A; Lötsch J; Oertel BG
Eur J Clin Pharmacol; 2021 May; 77(5):659-669. PubMed ID: 33201347
[TBL] [Abstract][Full Text] [Related]
27. Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry.
Pataj Z; Liebisch G; Schmitz G; Matysik S
J Chromatogr A; 2016 Mar; 1439():82-88. PubMed ID: 26607314
[TBL] [Abstract][Full Text] [Related]
28. Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers.
Gjestad C; Hole K; Haslemo T; Diczfalusy U; Molden E
AAPS J; 2019 Apr; 21(4):58. PubMed ID: 31020430
[TBL] [Abstract][Full Text] [Related]
29. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.
Diczfalusy U; Kanebratt KP; Bredberg E; Andersson TB; Böttiger Y; Bertilsson L
Br J Clin Pharmacol; 2009 Jan; 67(1):38-43. PubMed ID: 19006545
[TBL] [Abstract][Full Text] [Related]
30. Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics.
Gröer C; Busch D; Patrzyk M; Beyer K; Busemann A; Heidecke CD; Drozdzik M; Siegmund W; Oswald S
J Pharm Biomed Anal; 2014 Nov; 100():393-401. PubMed ID: 25218440
[TBL] [Abstract][Full Text] [Related]
31. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
[TBL] [Abstract][Full Text] [Related]
32. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
[TBL] [Abstract][Full Text] [Related]
33. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.
Naito T; Kubono N; Ishida T; Deguchi S; Sugihara M; Itoh H; Kanayama N; Kawakami J
Drug Metab Pharmacokinet; 2015 Dec; 30(6):419-24. PubMed ID: 26654672
[TBL] [Abstract][Full Text] [Related]
34. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man.
Lütjohann D; Marinova M; Schneider B; Oldenburg J; von Bergmann K; Bieber T; Björkhem I; Diczfalusy U
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):709-15. PubMed ID: 19954708
[TBL] [Abstract][Full Text] [Related]
35. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study.
Su Q; Li J; Ji X; Li J; Zhou T; Lu W; Li L
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 985():119-23. PubMed ID: 25678398
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of a method using supported liquid extraction for the simultaneous determination of midazolam and 1'-hydroxy-midazolam in human plasma by liquid chromatography with tandem mass spectrometry detection.
Svanström C; Hansson GP; Svensson LD; Sennbro CJ
J Pharm Biomed Anal; 2012 Jan; 58():71-7. PubMed ID: 21993197
[TBL] [Abstract][Full Text] [Related]
37. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
[TBL] [Abstract][Full Text] [Related]
38. LC-MS/MS method for the simultaneous quantification of intestinal CYP and UGT activity.
Busch D; Fritz A; Partecke LI; Heidecke CD; Oswald S
J Pharm Biomed Anal; 2018 Jun; 155():194-201. PubMed ID: 29649788
[TBL] [Abstract][Full Text] [Related]
39. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
Diczfalusy U; Nylén H; Elander P; Bertilsson L
Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
[TBL] [Abstract][Full Text] [Related]
40. Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.
Hole K; Heiberg PL; Gjestad C; Mehus LL; Rø Ø; Molden E
Pharmacol Res Perspect; 2018 Oct; 6(5):e00430. PubMed ID: 30214813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
